Drug
Dulaglutide clinical trials
Also written LY2189265.
- studies test it
- 80
- open now
- 9
- in phase 3
- 26
- first study started
- 2008
Keep track of what changes. Save the dulaglutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
80 studies that test it; most in 2010 (8)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 8 |
| 2011 | 8 |
| 2012 | 8 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 6 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 18
- Phase 2
- 17
- Phase 3
- 26
- Phase 4
- 17
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 49 · Other 31
Eli Lilly and Company (46) · University Hospital, Basel, Switzerland (4) · Zagazig University (2) · Ain Shams University (2) · Emory University (2) · Attikon Hospital (1) · Fundación para la Investigación del Hospital Clínico de Valencia (1) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1)
Often tested with
Tested in the same studies.
Semaglutide (4) · Tirzepatide (3) · Empagliflozin (2) · Sitagliptin (2) · Nisotirostide (2) · Dipeptidyl-Peptidase IV Inhibitors (1) · Metformin (1) · Canagliflozin (1)
Studies
Open first, then newest update. How each study uses dulaglutide is read from its arms, and is right about nine times in ten.
Testing it · 80
- Therapeutic Strategies for Microvascular Dysfunction in Type 1 DiabetesRecruitingPhase 2AdventHealth Translational Research InstituteNCT05478707Written as Dulaglutide
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)RecruitingPhase 3Eli Lilly and CompanyNCT06739122Written as Dulaglutide
- Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes MellitusEnrolling by invitationPhase 1/2Ain Shams UniversityNCT07319286Written as Dulaglutide
- GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose IntoleranceRecruitingPhase 2University of PennsylvaniaNCT04731272Written as Dulaglutide 0.75Mg/0.5Ml Inj Pen
- GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac SurgeryRecruitingPhase 4The University of Hong KongNCT06324461Written as Dulaglutide 0.75mg subcutaneous injection
- Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney DiseaseNot yet recruitingPhase 4First Affiliated Hospital of Wannan Medical CollegeNCT07537088Written as Dulaglutide
- Role of GLP1 RA Dulaglutide on Severe Intracranial AtherosclerosisRecruitingPhase 2/3National University of SingaporeNCT07282041Written as Dulaglutide
- The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With ObesityRecruitingNot applicableFirst Affiliated Hospital of Zhejiang UniversityNCT06331286Written as dulaglutide injection
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNot yet recruitingPhase 4Seoul National University Bundang HospitalNCT05140694Written as Dulaglutide
- Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesCompletedPhase 3Zagazig UniversityNCT07834398Written as Dulaglutide
- Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialCompletedPhase 3Zagazig UniversityNCT07820111Written as Dulaglutide 1.5 MG/ML
- Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.CompletedPhase 4Fundación para la Investigación del Hospital Clínico de ValenciaNCT06851962Written as Dulaglutide
- A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes MellitusCompletedPhase 1Eli Lilly and CompanyNCT07313813Written as Dulaglutide
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT04255433Written as Dulaglutide
- A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes MellitusCompletedPhase 3CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06235086Written as Dulaglutide
- Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent ThalassemiaCompletedPhase 2Ain Shams UniversityNCT07370922Written as Dulaglutide 0.75Mg/0.5Ml Inj Pen
- Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney DiseaseCompletedPhase 2Vanderbilt University Medical CenterNCT05254418Written as dulaglutide injection
- A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in IndiaCompletedPhase 4Eli Lilly and CompanyNCT05659537Written as Dulaglutide
- Perioperative Stress Hyperglycemia in General and Vascular Surgery PatientsTerminatedPhase 4Emory UniversityNCT04862234Written as Dulaglutide
- GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic ResponseCompletedPhase 4The University of Texas Health Science Center, HoustonNCT04387201Written as Dulaglutide
See all 80 studies that test dulaglutide →
Given in every arm · 2 — dulaglutide is usual care beside what is tested
- Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DMCompletedPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT04466904Written as Dulaglutide
- A Study of LY2189265 in Japanese Participants With Type 2 Diabetes MellitusCompletedPhase 3Eli Lilly and CompanyNCT01468181Written as LY2189265
As the comparator · 22 — what is tested is compared with dulaglutide
- A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesRecruitingPhase 3Eli Lilly and CompanyNCT07668336Written as Dulaglutide
- Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes MellitusNot yet recruitingPhase 2ProGen. Co., Ltd.NCT07677891Written as Dulaglutide
- A Phase 3 Study of HS-20094 in Patients With T2DMNot yet recruitingPhase 3Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07156539Written as Dulaglutide Injection
- A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or MetforminRecruitingPhase 2Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07109700Written as Dulaglutide 1.5 MG
- A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminActive, not recruitingPhase 3Beijing Dongfang Biotech Co., Ltd.NCT06257966Written as Dulaglutide
- A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)CompletedPhase 4Eli Lilly and CompanyNCT05564039Written as Dulaglutide
- A Study of HS-20094 in Patients With T2DMCompletedPhase 2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06901648Written as Dulaglutide
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DMCompletedPhase 3Hangzhou Sciwind Biosciences Co., Ltd.NCT05680129Written as Dulaglutide
- A Study of LY3493269 in Participants With Type 2 DiabetesCompletedPhase 1Eli Lilly and CompanyNCT04515576Written as Dulaglutide
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes MellitusCompletedPhase 1Fujian Shengdi Pharmaceutical Co., Ltd.NCT05516966Written as Dulaglutide Injection
- A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)CompletedPhase 1Eli Lilly and CompanyNCT02759107Written as Dulaglutide
- A Study of LY3502970 in Participants With Type 2 Diabetes MellitusCompletedPhase 2Eli Lilly and CompanyNCT05048719Written as Dulaglutide
- A Study of LY3437943 in Participants With Type 2 DiabetesCompletedPhase 2Eli Lilly and CompanyNCT04867785Written as Dulaglutide
- The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.Status unknownPhase 4Second Xiangya Hospital of Central South UniversityNCT05005741Written as Dulaglutide
- A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese SubjectsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT05459285Written as dulaglutide injection
- A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 DiabetesCompletedPhase 3Eli Lilly and CompanyNCT03861052Written as Dulaglutide
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension PeriodCompletedPhase 3SanofiNCT02787551Written as dulaglutide
- Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With MetforminTerminatedPhase 3SanofiNCT03684642Written as Dulaglutide
- Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 DiabetesCompletedPhase 3Novo Nordisk A/SNCT03015220Written as Dulaglutide
- A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 1Eli Lilly and CompanyNCT04143802Written as Dulaglutide
Showing 20 of 22.
Codes
What other systems call dulaglutide · ClinicalTrials.gg INT005774
- MeSH (NLM) C555680dulaglutideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) WTT295HSY5DULAGLUTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1551291Confirmed FDA, Wikidata
- Wikidata Q21011228dulaglutideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169923DulaglutideOne source FDA
- DrugBank DB09045One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C555680 | dulaglutide | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | WTT295HSY5 | DULAGLUTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1551291 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011228 | dulaglutide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169923 | Dulaglutide | One source FDA |
| DrugBank | DB09045 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.